Funding and Grants

  1. Department of Biotechnology- Biotechnology Industry Research Assistance Council (DBT-BIRAC) has funded project on 25 November 2020 on “Therapeutic Antibodies for COVID-19” under strategic funding for Covid-19 Consortium under National Biopharma Mission for a total cost of Rs. 16.5664 crores, with support of Rs. 10.705 crores to the CIIDRET, UDSC and Rs. 5.8614 crores to M/s. Gennova Biopharmaceuticals Limited for 15 months.
  2. DBT, Govt. of India has approved DBT-supported Genomic Facility at University of Delhi South Campus till 2020 with a total outlay of approx. Rs. 200 Lakhs. This facility includes Sanger’s DNA Sequencing using 96- and 16- capillary Applied Biosystems machines, Microarray on Agilent platform and Next Generation Sequencing on MiSeq platform. (PI, Prof. Vijay K. Chaudhary; Co-PI, Dr. Amita Gupta).
  3. DBT, Govt. of India has approved a project Identification of mycobacterial proteins and novel antigenic epitopes having immunodiagnostic potential and development of reagents for point of care test for tuberculosis till 2020 with total outlay of approx. Rs. 99 Lakhs with NITRD, New Delhi as the Clinical Collaborator. (PI, Dr. Amita Gupta; Co-PI, Prof. Vijay K. Chaudhary, NITRD Co-PI, Dr. Rohit Sarin).
  4. A Centre of excellence entitled ―Antibody Technology: Research for Therapeutic and Diagnostic Application‖ has been recommended by the DBT Task Force for financial support of approximately Rs. 7 crore. The final sanction letter is expected in the next financial year.